Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin

Kidney International

Volumn 60, Issue 5, 2001, Pages 1910-1916

  Hayashi, Kunihiko ^a   Hasegawa, Kaname ^a   Kobayashi, Shin ^a  

^a KIRIN BREWERY CO LTD   (Japan)

Author keywords

Blood pressure; Erythropoiesis; Hematocrit; Hemodialysis; Hypertension; Kidney; Quality of life; Renal anemia

Indexed keywords

ALACEPRIL; BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; IMIDAPRIL; LISINOPRIL; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFECT; EVALUATION; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL;

EID: 0034783689     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.00028.x     Document Type: Article

References (24)

1. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?
2. Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients
3. High dose enalapril impairs the response to erythropoietin treatment in heamodialysis patients
4. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients
5. Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease
6. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice
7. Angiotensin II stimulates proliferation of normal early erythroid progenitors
8. Angiotensin II increase erythropoietin production in healthy volunteers
9. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-asparly-lysyl-proline
10. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentration
11. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme
12. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo
13. Inhibitor of hematopoietic pluripotent stem cell proliferation: Purification and determination of its structure
14. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients
15. ACE inhibitors do not decrease rHuEPO response in patients with end-stage renal failure
16. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?
17. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
18. The central role of propensity score in observational studies for causal inference
19. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group
20. Matching using estimated propensity scores: Relating theory to practice
21. NKF-DOQI: Clinical practice guidelines for the treatment of anemia of chronic renal failure
22. ACE inhibitors and erythropoietin response in hemodialysis patients